[HTML][HTML] Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon
G Mombo-Ngoma, C Kleine, A Basra, H Würbel… - Malaria journal, 2012 - Springer
Malaria journal, 2012•Springer
Background The recommendation of artemisinin combination therapy (ACT) as first-line
treatment for uncomplicated falciparum malaria is supported by a plethora of high quality
clinical trials. However, their recommendation for the treatment of mixed-species malaria
and the large-scale use for the treatment of non-falciparum malaria in endemic regions is
based on anecdotal rather than systematic clinical evidence. Methods This study
prospectively observed the efficacy of artemether-lumefantrine for the treatment of …
treatment for uncomplicated falciparum malaria is supported by a plethora of high quality
clinical trials. However, their recommendation for the treatment of mixed-species malaria
and the large-scale use for the treatment of non-falciparum malaria in endemic regions is
based on anecdotal rather than systematic clinical evidence. Methods This study
prospectively observed the efficacy of artemether-lumefantrine for the treatment of …
Background
The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence.
Methods
This study prospectively observed the efficacy of artemether-lumefantrine for the treatment of uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country of Gabon.
Results
Forty patients suffering from uncomplicated Plasmodium malariae, Plasmodium ovale or mixed-species malaria (including Plasmodium falciparum) presenting at the hospital received artemether-lumefantrine treatment and were followed up. All evaluable patients (n = 38) showed an adequate clinical and parasitological response on Day 28 after oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to moderate intensity and completely resolved by the end of study.
Conclusions
This first systematic assessment of artemether-lumefantrine treatment for P. malariae, P. ovale and mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite species differentiation, with artemether-lumefantrine in Gabon.
Trial Registration
ClinicalTrials.gov Identifier: NCT00725777
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果